2-benzenesulfonamidopyrimidine: sulfadiazine metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 152190 |
| CHEMBL ID | 608694 |
| SCHEMBL ID | 332569 |
| MeSH ID | M0091695 |
| Synonym |
|---|
| OPREA1_171203 |
| n-pyrimidin-2-yl-benzenesulfonamide |
| AG-690/33036027 |
| n-(2-pyrimidinyl)benzenesulfonamide |
| CBDIVE_011066 |
| OPREA1_583200 |
| smr000504939 |
| MLS001212372 |
| STK001937 |
| n-(pyrimidin-2-yl)benzenesulfonamide |
| 2-benzenesulfonamidopyrimidine |
| n-pyrimidin-2-ylbenzenesulfonamide |
| CHEMBL608694 |
| AKOS000668930 |
| HMS1608F14 |
| NCGC00245018-01 |
| (phenylsulfonyl)pyrimidin-2-ylamine |
| 16699-12-0 |
| unii-56u088ayd6 |
| benzenesulfonamide, n-2-pyrimidinyl- |
| 56u088ayd6 , |
| HMS2843M06 |
| SCHEMBL332569 |
| 2-aminopyrimidinebenzenesulfonamide |
| 2-(phenylsulfonamido)pyrimidine |
| 2-(n-(phenylsulfonyl)amino)pyrimidine |
| DTXSID20168217 |
| AS-60065 |
| mfcd00447813 |
| Q27261434 |
| SB58777 |
| CS-0313061 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 28.1838 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 39.8107 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| GLS protein | Homo sapiens (human) | Potency | 31.6228 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 22.7265 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 44.6684 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.1585 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 79.4328 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 23.7781 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID454753 | Antileishmanial activity against Leishmania infantum MCAN/ES/92/BCN 83 promastigotes at 100 ug/ml after 48 hrs by resazurin method | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21 | In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide. |
| AID454754 | Antileishmanial activity against Leishmania infantum MCAN/ES/92/BCN 83 promastigotes after 48 hrs by resazurin method | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21 | In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide. |
| AID454755 | Cytotoxicity against mouse J774 cells after 24 hrs by by resazurin reduction test | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21 | In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||